AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28073037 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron amino acid chelate (IAAC)
Number of subjects: 150
Study 28073037 — intervention group
Group type: COMPARATOR
Intervention: Ferrous fumarate (FF)
Number of subjects: 150
Study 27647061 — intervention group
Group type: EXPERIMENTAL
Intervention: AR+IVR
Number of subjects: 898
Study 27647061 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 898
Study 24418359 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 142
Study 23062232 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) - S-1 40 mg/m(2) twice daily on days 1-14 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks for up to 9 cycles.
Number of subjects: 340
Study 23062232 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (CapeOX) - capecitabine 1000 mg/m(2) twice daily on days 1-14 and oxaliplatin 130 mg/m(2) on day 1, repeated every 3 weeks for up to 9 cycles.
Number of subjects: 340
Study 23062232 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX)
Number of subjects: 340
Study 23062232 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (CapeOX)
Number of subjects: 340
Study 19548076 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionyl-carnitine (LPC) 1.2 g/day + PGE-1 60 mg/day
Number of subjects: 75
Study 19548076 — intervention group
Group type: COMPARATOR
Intervention: PGE-1 only
Number of subjects: 75
Study 17447874 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intervention (both physical activity and fat intake interventions at baseline)
Number of subjects: 392
Study 17447874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention (physical activity first, then fat intake 3 months later)
Number of subjects: 392
Study 17447874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention (fat intake first, then physical activity 3 months later)
Number of subjects: 392
Study 17447874 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall interventions (both modes)
Number of subjects: 392
Study 12699520 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micro g of sufentanil + 500 micro g of adenosine
Number of subjects: 25
Study 12699520 — intervention group
Group type: COMPARATOR
Intervention: 10 micro g of sufentanil
Number of subjects: 25
Study 10895027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (5 mg), repeated if necessary
Number of subjects: 60
Study 10895027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10895027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate
Number of subjects: 60
Study 8826608 — intervention group
Group type: COMPARATOR
Intervention: Daily oral etoposide alone for 21 days (arm A)
Number of subjects: 39
Study 8826608 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral etoposide for 21 days with GM‐CSF, 250 micrograms/m2, s.c. twice daily for the first 10 days of etoposide administration (arm B)
Number of subjects: 39
Study 8826608 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral etoposide for 21 days with GM‐CSF twice daily for the sixth through second days preceding etoposide administration (arm C)
Number of subjects: 39
Study 1360464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilest (ethinyl estradiol 35 micrograms and norgestimate 250 mg) for 21 days, followed by 1-4 days of missed pills depending on the group.
Number of subjects: 47
Study 1360464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no missed pills)
Number of subjects: 47
Study 1360464 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2a (missed 1 day on day 6)
Number of subjects: 47
Study 1360464 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3a (missed 3 days on day 18)
Number of subjects: 47
Study 4072647 — intervention group
Group type: EXPERIMENTAL
Intervention: Thornton nail
Number of subjects: 94
Study 4072647 — intervention group
Group type: EXPERIMENTAL
Intervention: Scand hip pins
Number of subjects: 94
Study 4072647 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaction by hammer
Number of subjects: 94
Study 4072647 — intervention group
Group type: COMPARATOR
Intervention: No impaction
Number of subjects: 94
Study 30891813 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG/hMG for 3 months
Number of subjects: 0
Study 30891813 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 0
Study 28795880 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation therapy (EST), used four times daily for 20 minutes per session
Number of subjects: 23
Study 28795880 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (no electric stimulation therapy)
Number of subjects: 23
Study 28795880 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation therapy (EST)
Number of subjects: 23
Study 26053726 — intervention group
Group type: EXPERIMENTAL
Intervention: (68)Ga DOTATATE PET/CT
Number of subjects: 54
Study 26053726 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (for patients with negative scans)
Number of subjects: 54
Study 23580456 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 ml nitrate‐rich concentrated beetroot juice (BR)
Number of subjects: 8
Study 23580456 — intervention group
Group type: COMPARATOR
Intervention: Tomato juice (placebo [PLA])
Number of subjects: 8
Study 21135862 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment (Ph)
Number of subjects: 47
Study 21135862 — intervention group
Group type: COMPARATOR
Intervention: Osteopathic treatment (Os)
Number of subjects: 47
Study 21135862 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pharmacological and osteopathic treatment (PhO)
Number of subjects: 47
Study 19474795 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (7.5-15 mg per day)
Number of subjects: 128
Study 19474795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 17373905 — intervention group
Group type: EXPERIMENTAL
Intervention: PANVAC™ cancer vaccine therapy delivered through recombinant vaccinia and recombinant fowlpox vectors, injected subcutaneously.
Number of subjects: 0
Study 17373905 — intervention group
Group type: EXPERIMENTAL
Intervention: PANVAC™ in combination with conventional chemotherapy and/or radiation.
Number of subjects: 0
Study 17373905 — intervention group
Group type: EXPERIMENTAL
Intervention: PANVAC™ alone.
Number of subjects: 0
Study 15466063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (clinicians saw the screening test results and a telephone-based parenting education program was available)
Number of subjects: 224
Study 15466063 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinicians did not see the screening test results)
Number of subjects: 224
Study 11588322 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH 12 500 IU SC BID
Number of subjects: 3169
Study 11588322 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH 5000 IU SC BID
Number of subjects: 3169
Study 11588322 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 3169
Study 12160204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tobramycin and metronidazole for three days prior to surgery
Number of subjects: 137
Study 12160204 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotic cefmetazole every 3 hours during surgery
Number of subjects: 137
Study 12160204 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotic cefmetazole every 3 hours during surgery and luminal preparation of tobramycin during surgery
Number of subjects: 137
Study 8276939 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 3793028 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary extracts from female donors
Number of subjects: 0
Study 3793028 — intervention group
Group type: COMPARATOR
Intervention: Blank/ethanol
Number of subjects: 0
Study 31574170 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L polyethylene glycol plus ascorbic acid with bisacodyl suppository
Number of subjects: 168
Study 31574170 — intervention group
Group type: COMPARATOR
Intervention: 2 L polyethylene glycol plus ascorbic acid
Number of subjects: 168
Study 31421096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Hybrid Therapy (BHT)
Number of subjects: 44
Study 31421096 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted Therapy (RT)
Number of subjects: 44
Study 31421096 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Hybrid Therapy (UHT)
Number of subjects: 44
Study 29135426 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Supported Employment (ISE)
Number of subjects: 162
Study 29135426 — intervention group
Group type: COMPARATOR
Intervention: Individual Placement and Support (IPS)
Number of subjects: 162
Study 29135426 — intervention group
Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 162
Study 26133561 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC spray with no rubbing
Number of subjects: 50
Study 26133561 — intervention group
Group type: COMPARATOR
Intervention: TAC spray with rubbing
Number of subjects: 50
Study 23804385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Capture 2 (HC2) test
Number of subjects: 2920
Study 21633800 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance motor information conditions
Number of subjects: 13
Study 21633800 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of disease onset
Number of subjects: 13
Study 21633800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar impairment
Number of subjects: 13
Study 21633800 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 13
Study 20166436 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine hydrochloride determination method using LC-MS in human plasma (0.5 ml)
Number of subjects: 0
Study 20166436 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine hydrochloride determination method using LC-MS in human urine (0.1 ml)
Number of subjects: 0
Study 16723363 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndromic STI packages (containing antibiotics, condoms, partner notification cards, and written information)
Number of subjects: 525
Study 15312096 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2-containing mouthrinse
Number of subjects: 18
Study 15312096 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse
Number of subjects: 18
Study 11416871 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (INO) weaning from 40 ppm
Number of subjects: 84
Study 11416871 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of INO
Number of subjects: 84
Study 11416871 — intervention group
Group type: EXPERIMENTAL
Intervention: INO weaning with surfactant therapy
Number of subjects: 84
Study 11416871 — intervention group
Group type: EXPERIMENTAL
Intervention: INO weaning with specific dose reduction
Number of subjects: 84
Study 11416871 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewean PaO(2)
Number of subjects: 84
Study 9576635 — intervention group
Group type: EXPERIMENTAL
Intervention: CD18 immunofluorescence measurement in patients with acute ischemic stroke
Number of subjects: 20
Study 9576635 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients with other neurological diseases)
Number of subjects: 20
Study 7889886 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron supplementation
Number of subjects: 28
Study 7889886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3259128 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft (Group 1)
Number of subjects: 80
Study 3259128 — intervention group
Group type: EXPERIMENTAL
Intervention: Left internal mammary artery graft (Group 2)
Number of subjects: 80
Study 31928077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher iron status (as determined by SNPs)
Number of subjects: 0
Study 31928077 — intervention group
Group type: COMPARATOR
Intervention: Lower iron status (as determined by SNPs)
Number of subjects: 0
Study 29957756 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue metformin during peri-angiography (M (+) group)
Number of subjects: 162
Study 29957756 — intervention group
Group type: COMPARATOR
Intervention: Stop metformin 24 hours prior to procedure (M (−) group)
Number of subjects: 162
Study 26202461 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioural therapy (TF-CBT)
Number of subjects: 26
Study 26485477 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenohumeral posterior mobilization technique after training with a cycle ergometer
Number of subjects: 57
Study 26485477 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 57
Study 23312430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive refocusing treatment for insomnia (CRT-I) + sleep hygiene education (SH)
Number of subjects: 51
Study 23312430 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (SH)
Number of subjects: 51
Study 21677695 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (ARB)
Number of subjects: 113
Study 21677695 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (CCB)
Number of subjects: 113
Study 19086244 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (400 mg t.i.d.)
Number of subjects: 38
Study 19086244 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium difficile immune whey (CDIW) (200 ml t.i.d.)
Number of subjects: 38
Study 16863724 — intervention group
Group type: EXPERIMENTAL
Intervention: Clover honey (50 g carbohydrate)
Number of subjects: 12
Study 16863724 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat honey (50 g carbohydrate)
Number of subjects: 12
Study 16863724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton honey (50 g carbohydrate)
Number of subjects: 12
Study 16863724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tupelo honey (50 g carbohydrate)
Number of subjects: 12
Study 16863724 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (50 g carbohydrate)
Number of subjects: 12
Study 12880704 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with diabetes and a history of recurrent plantar ulcers
Number of subjects: 30
Study 10858637 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal support from a community midwifery support worker (SW) offering ten visits in the first 28 days postnatally, for up to 3 hours per day.
Number of subjects: 623
Study 10858637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postnatal support).
Number of subjects: 623
Study 8653433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 248
Study 8653433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 2302973 — intervention group
Group type: COMPARATOR
Intervention: Solid boluses (yogurt and gelatin)
Number of subjects: 20
Study 2302973 — intervention group
Group type: EXPERIMENTAL
Intervention: Water bolus
Number of subjects: 20
Study 2302973 — intervention group
Group type: EXPERIMENTAL
Intervention: Boluses with varying temperatures (1°C to 60°C)
Number of subjects: 20
Study 6103450 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-glucose self-monitoring (meter)
Number of subjects: 13
Study 6103450 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally treated (non-meter)
Number of subjects: 13
Study 6103450 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant women (control)
Number of subjects: 13
Study 6103450 — intervention group
Group type: EXPERIMENTAL
Intervention: Home control
Number of subjects: 13
Study 6103450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 13
Study 31714309 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative intravenous co‐amoxiclav
Number of subjects: 293
Study 31714309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 293
Study 30399442 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation Services (PNs) intervention
Number of subjects: 300
Study 28407505 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO-provision early (at inclusion)
Number of subjects: 20
Study 25452632 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation
Number of subjects: 538
Study 25452632 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric rehabilitation
Number of subjects: 538
Study 25452632 — intervention group
Group type: COMPARATOR
Intervention: Control group (health centre hospital rehabilitation)
Number of subjects: 538
Study 24369397 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional jejunal interposition (FJI)
Number of subjects: 109
Study 24369397 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y (R-Y)
Number of subjects: 109
Study 24369397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study 21738025 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (50 mg/d, titrated up to 200 mg/d)
Number of subjects: 80
Study 21738025 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (25 mg/d, titrated up to 100 mg/d)
Number of subjects: 80
Study 19824837 — intervention group
Group type: EXPERIMENTAL
Intervention: Respeto/Proteger: Respecting and Protecting Our Relationships program; details on dosage and duration not available.
Number of subjects: 0
Study 19824837 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental protectiveness; details on dosage and duration not available.
Number of subjects: 0
Study 16395251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (VC) infusion, n=20
Number of subjects: 80
Study 16395251 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (VE)-coated dialyzer, n=20
Number of subjects: 80
Study 16395251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C plus VE-coated dialyzer, n=20
Number of subjects: 80
Study 16395251 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group), n=20
Number of subjects: 80
Study 15248137 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/NVP
Number of subjects: 127
Study 15248137 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC/NFV
Number of subjects: 127
Study 11032269 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 27
Study 11032269 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 27
Study 9023238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (KT)
Number of subjects: 80
Study 9023238 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (MP)
Number of subjects: 80
Study 7974894 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapy
Number of subjects: 0
Study 7974894 — intervention group
Group type: COMPARATOR
Intervention: Cytokine therapy
Number of subjects: 0
Study 7974894 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive nephrectomy
Number of subjects: 0
Study 3589707 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 197
Study 3589707 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 197
Study 30538796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (200 mg intraoperative, 100 mg postoperative every 8 hours for 2 days)
Number of subjects: 49
Study 30538796 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 49
Study 27879595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet of surgical risks
Number of subjects: 60
Study 27879595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 60
Study 27879595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet group
Number of subjects: 60
Study 27879595 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27879595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading about surgery
Number of subjects: 60
Study 24710974 — intervention group
Group type: COMPARATOR
Intervention: OT
Number of subjects: 30
Study 24710974 — intervention group
Group type: EXPERIMENTAL
Intervention: OT plus EMG‐biofeedback therapy
Number of subjects: 30
Study 24710974 — intervention group
Group type: EXPERIMENTAL
Intervention: OT plus neurofeedback therapy
Number of subjects: 30
Study 22392815 — intervention group
Group type: EXPERIMENTAL
Intervention: Union commitment
Number of subjects: 1817
Study 22392815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to dust
Number of subjects: 1817
Study 22392815 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to chemicals
Number of subjects: 1817
Study 22392815 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about exposure to occupational hazards
Number of subjects: 1817
Study 20032498 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular remission (MR) after rituximab-based induction treatment
Number of subjects: 259
Study 20032498 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular remission (MR) in bone marrow (BM) MRD-negative complete response (CR) and partial response (PR)
Number of subjects: 259
Study 20032498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained molecular remission (MR) during postinduction period
Number of subjects: 259
Study 20032498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained molecular remission (MR) during maintenance in MCL Elderly
Number of subjects: 259
Study 20032498 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 259
Study 18096137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg/day) + Transdermal Nicotine Patch (21 mg/24h)
Number of subjects: 58
Study 18096137 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Transdermal Nicotine Patch (21 mg/24h)
Number of subjects: 58
Study 16155368 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg subcutaneously twice weekly for 4 weeks)
Number of subjects: 20
Study 16155368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 12799329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐abdominal operations
Number of subjects: 1021
Study 9920522 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PLTP activity
Number of subjects: 52